Ranbaxy inches up on plan to re-launch its former flagship brand Sotret in US

21 May 2012 Evaluate

Ranbaxy Laboratories is currently trading at Rs. 491.25, up by 4.60 points or 0.95% from its previous closing of Rs. 486.65 on the BSE.

The scrip opened at Rs. 486.40 and has touched a high and low of Rs. 496.00 and Rs. 486.20 respectively. So far 15395 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 570.00 on 02-Aug-2011 and a 52 week low of Rs. 366.50 on 19-Dec-2011.

Last one week high and low of the scrip stood at Rs. 505.00 and Rs. 475.90 respectively. The current market cap of the company is Rs. 20763.72 crore.

The promoters holding in the company stood at 63.67% while Institutions and Non-Institutions held 20.47% and 13.82% respectively.

Ranbaxy Laboratories’ former flagship skincare brand Sotret will soon be re-launched in the US through Cipher Pharmaceuticals, a Canada based company. The final review of the drug will be conducted on May 29, 2012 by the US drug regulator - USFDA.

Sotret along with other 30 drugs were banned in September 2008 by the USFDA for violating US drug manufacturing norms. Prior to the ban, Sotret had generated approximately $50 million in annual sales and was Ranbaxy's third best selling drug globally.

Cipher is the marketing partner for Sotret which specializes in developing improved formulations of existing drugs out-licenses them to partners for a fee.

Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×